Lilly expects to soon announce late-stage clinical trial results for two biotech drugs designed to slow the inflammation caused by autoimmune diseases. By the end of the year, it will announce results for a third.
The state has enjoyed success funding and building life sciences companies, and the new Indiana Biosciences Research Institute should give it a further boost, according to panelists Friday at IBJ's Life Sciences Power Breakfast.
To satisfy patients with high-deductible health plans, Northwest Radiology has introduced flat-rate pricing for its imaging scans. It’s a centuries-old concept among postal services, but for health care, it’s revolutionary.
The Indianapolis-based maker of genetically modified seed traits and weed killers said Thursday that it earned $409 million before interest, taxes, depreciation and amortization, down by 19 percent from the same quarter a year ago.
Things got quiet after a wave of hospital systems' acquiring physician practices swept through central Indiana from 2008 to 2011. But a new wave could start now that Congress passed the "doc fix" last week.
AIT Labs and its former executives have already incurred nearly $5 million defending themselves against charges by the U.S. Department of Labor that AIT founder Michael Evans sold the company to its employees in 2009 at an inflated price.
By subtly threatening the loss of patients via a new "reference lab network," the Indianapolis-based health insurer has persuaded 63 Indiana hospitals to slash their prices for blood and tissue testing by as much as 80 percent—beyond the discounts Anthem had already negotiated with them.
Hospitals and doctors still aren’t seeing a wave of new patients because rising deductibles in patients' health plans are continuing to delay medical procedures, even though their job prospects are better than they’ve been in years.